Bausch + Lomb (NYSE:BLCO) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Bausch + Lomb (NYSE:BLCO) announced its earnings results on Wednesday. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.02, Zacks reports. The company had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.26 billion. Bausch + Lomb had a positive return on equity of 3.17% and a negative net margin of 7.86%. Bausch + Lomb’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period last year, the business posted $0.24 EPS. Bausch + Lomb updated its FY 2025 guidance to EPS.

Bausch + Lomb Price Performance

Shares of NYSE BLCO opened at $16.29 on Thursday. The stock’s 50-day simple moving average is $17.47 and its 200-day simple moving average is $18.15. The firm has a market capitalization of $5.74 billion, a PE ratio of -15.51, a price-to-earnings-growth ratio of 2.17 and a beta of 0.46. Bausch + Lomb has a fifty-two week low of $13.16 and a fifty-two week high of $21.69. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.57.

Wall Street Analysts Forecast Growth

BLCO has been the subject of several recent research reports. Needham & Company LLC reissued a “hold” rating on shares of Bausch + Lomb in a research note on Thursday, October 31st. Wells Fargo & Company decreased their price target on shares of Bausch + Lomb from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Thursday, January 16th. Stifel Nicolaus dropped their price target on shares of Bausch + Lomb from $19.00 to $18.00 and set a “hold” rating for the company in a research note on Wednesday, January 29th. Morgan Stanley cut Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 price objective on the stock. in a research note on Monday, December 2nd. Finally, Bank of America reissued an “underperform” rating and set a $18.00 target price on shares of Bausch + Lomb in a research note on Thursday, December 12th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $20.25.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.